Will Pricing For Gilead’s Sovaldi Set A Ceiling In HCV, Lead To A Price War?
Executive Summary
Gilead’s wholesale acquisition cost of $1,000-a-day for Sovaldi met with immediate backlash, as well as foreboding comments from a leading PBM. Observers anticipate a possible pricing war between Gilead and other companies developing new regimens for HCV.
You may also be interested in...
Paying For Obesity Drugs: The Looming Affordability Crisis
As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.
Paying For Obesity Drugs: The Looming Affordability Crisis
As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.
10 Triumphant Drug Launches Of The Decade
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.